Subtype
Urinary Tract Neoplasm
CI-CAN-00001627Explore in graph →
Non-malignant558 active trials14 approved drugs29 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001627Explore in graph →
Clinical trials
2,187 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05030077 | Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma | unknown | Phase 2 | 53 | Tianjin Medical University Second HospitalOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT04066595 | Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma.(CabUC) | terminated | Phase 2 | 7 | Johannes Gutenberg University MainzOTHER | 1 | Aug 30, 2021 |
| clinicaltrials |
| NCT05016973 | A Clinical Study of RC48-ADC Combined With Triplizumab For Treatment of Myometrial Invasive Bladder Cancer | unknown | Phase 2 | 25 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Aug 23, 2021 | clinicaltrials |
| NCT00694915 | Study of Mycobacterium w in Superficial Transitional Cell Carcinoma of Bladder(STCC) | completed | Phase 2 | 122 | Cadila PharnmaceuticalsINDUSTRY | 1 | Aug 17, 2021 | clinicaltrials |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | completed | Phase 1 / Phase 2 | 515 | Gilead SciencesINDUSTRY | 1 | Aug 12, 2021 | clinicaltrials |
| NCT05001763 | Prucalopride for Postoperative Ileus in Patients Undergoing Robot-assisted Laparoscopic Radical Cystectomy | unknown | Phase 2 | 160 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 0 | Aug 12, 2021 | clinicaltrials |
| NCT04579133 | Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy | terminated | Phase 2 | 140 | Latin American Cooperative Oncology GroupOTHER | 1 | Jun 16, 2021 | clinicaltrials |
| NCT04922047 | Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01)(TACBIN-01) | unknown | Phase 1 / Phase 2 | 6 | RenJi HospitalOTHER | 1 | Jun 11, 2021 | clinicaltrials |
| NCT00118040 | Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jun 10, 2021 | clinicaltrials |
| NCT02009332 | Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer | completed | Phase 1 / Phase 2 | 21 | Aadi Bioscience, Inc.INDUSTRY | 1 | Jun 8, 2021 | clinicaltrials |
| NCT04909775 | Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder Cancer | unknown | Phase 2 | 40 | Ruijin HospitalOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT02693717 | Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial Cancer | terminated | Phase 2 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2021 | clinicaltrials |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | withdrawn | Phase 1 / Phase 2 | 0 | NKGen Biotech, Inc.INDUSTRY | 0 | May 12, 2021 | clinicaltrials |
| NCT04878250 | Preoperative Bintrafusp Alfa in Operable Urothelial Carcinoma of the Bladder(PEBBLE) | unknown | Phase 2 | 49 | Queen Mary University of LondonOTHER | 0 | May 7, 2021 | clinicaltrials |
| NCT01827943 | Phase II Evaluating Efficacy of Temsirolimus in 2 Line Therapy for Patients With Advanced Bladder Cancer(VESTOR) | completed | Phase 2 | 54 | Institut BergoniéOTHER | 1 | May 6, 2021 | clinicaltrials |
| NCT01438112 | Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer(BOND) | terminated | Phase 2 / Phase 3 | 22 | CG Oncology, Inc.INDUSTRY | 1 | Apr 14, 2021 | clinicaltrials |
| NCT02365818 | Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure(BOND2) | completed | Phase 2 | 66 | CG Oncology, Inc.INDUSTRY | 1 | Apr 14, 2021 | clinicaltrials |
| NCT02552121 | Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 33 | Seagen Inc.INDUSTRY | 5 | Apr 8, 2021 | clinicaltrials |
| NCT03824691 | hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study"(ARCADIA) | unknown | Phase 2 | 122 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Feb 25, 2021 | clinicaltrials |
| NCT00006111 | Surgery Plus Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Urinary Tract | completed | Phase 2 | 53 | UNICANCEROTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT04383067 | A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients | unknown | Phase 2 | 20 | Sheba Medical CenterOTHER_GOV | 1 | Feb 11, 2021 | clinicaltrials |
| NCT04738630 | Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer | unknown | Phase 2 | 110 | Taizhou Hanzhong biomedical co. LTDINDUSTRY | 1 | Feb 4, 2021 | clinicaltrials |
| NCT04184232 | Treatment of Recurrent Bladder Cancer With Dendritic Cells | completed | Phase 2 | 17 | Institute of Biophysics and Cell Engineering of National Academy of Sciences of BelarusOTHER_GOV | 1 | Jan 22, 2021 | clinicaltrials |
| NCT02197897 | Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors(BCTamoxifen) | completed | Phase 2 | 15 | Baylor College of MedicineOTHER | 1 | Jan 13, 2021 | clinicaltrials |
| NCT04661826 | ONCOFID-P-B in the Intravescical Therapy of Patients With Non-muscle Invasive Cancer of the Bladder. | completed | Phase 2 | 60 | Fidia Farmaceutici s.p.a.INDUSTRY | 3 | Dec 10, 2020 | clinicaltrials |
| NCT04644432 | Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma(INDIGO) | unknown | Phase 2 | 30 | Herlev and Gentofte HospitalOTHER | 1 | Nov 25, 2020 | clinicaltrials |
| NCT02780687 | Afatinib Monotherapy in Patients With ERBB-deregulated Metastatic Urothelial Tract Carcinoma After Failure of Platinum Based Chemotherapy(LUX-Bladder 1) | completed | Phase 2 | 42 | Boehringer IngelheimINDUSTRY | 3 | Nov 18, 2020 | clinicaltrials |
| NCT04211012 | A Study on Toripalimab Plus Nab-Paclitaxel With or Without Cisplatin as First-line Treatment of Urothelial Carcinoma | unknown | Phase 2 | 30 | Jun GuoOTHER | 1 | Nov 13, 2020 | clinicaltrials |
| NCT02788201 | Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma | completed | Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Nov 6, 2020 | clinicaltrials |
| NCT00003930 | Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer | completed | Phase 1 / Phase 2 | 84 | Radiation Therapy Oncology GroupNETWORK | 2 | Oct 20, 2020 | clinicaltrials |
| NCT00478361 | Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function | completed | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 9, 2020 | clinicaltrials |
| NCT03113266 | Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma | unknown | Phase 2 | 370 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Sep 30, 2020 | clinicaltrials |
| NCT00749892 | Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer | completed | Phase 2 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 10, 2020 | clinicaltrials |
| NCT03498196 | A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer | terminated | Phase 1 / Phase 2 | 1 | Baylor College of MedicineOTHER | 1 | Aug 24, 2020 | clinicaltrials |
| NCT03719300 | Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC | terminated | Phase 2 | 32 | Anchiano Therapeutics Israel Ltd.INDUSTRY | 1 | Aug 19, 2020 | clinicaltrials |
| NCT00088946 | Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer | completed | Phase 2 | 17 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT03167151 | Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)(PemBla) | terminated | Phase 1 / Phase 2 | 6 | University of OxfordOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT04493489 | Propranolol Adjuvant Treatment of Bladder Cancer | unknown | Phase 2 | 242 | Central South UniversityOTHER | 0 | Jul 30, 2020 | clinicaltrials |
| NCT04219046 | Evaluation of Naloxegol in the Prevention of POI After Cystectomy(ANTAGOCYST) | unknown | Phase 2 | 102 | Institut Paoli-CalmettesOTHER | 0 | Jul 28, 2020 | clinicaltrials |
| NCT03672240 | Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment(NMIBC) | completed | Phase 1 / Phase 2 | 6 | Asieris Pharmaceutical Technologies Co., Ltd.INDUSTRY | 1 | Jul 20, 2020 | clinicaltrials |
| NCT02169284 | Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery | terminated | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jul 7, 2020 | clinicaltrials |
| NCT02447549 | Study of Tumour Focused Radiotherapy for Bladder Cancer(RAIDER) | active not recruiting | Phase 2 | 345 | Institute of Cancer Research, United KingdomOTHER | 3 | Jun 9, 2020 | clinicaltrials |
| NCT03517995 | Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention | withdrawn | Phase 2 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 28, 2020 | clinicaltrials |
| NCT00462488 | Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ | completed | Phase 2 | 46 | Sesen Bio, Inc.INDUSTRY | 2 | May 12, 2020 | clinicaltrials |
| NCT03534492 | Durvalumab Plus Olaparib Administered Prior to Surgery of Resectable Urothelial Bladder Cancer (NEODURVARIB)(NEODURVARIB) | completed | Phase 2 | 29 | Spanish Oncology Genito-Urinary GroupOTHER | 1 | Apr 6, 2020 | clinicaltrials |
| NCT02070120 | Investigating Bladder Chemotherapy Instead of Surgery for Low Risk Bladder Cancer(CALIBER) | unknown | Phase 2 | 82 | Institute of Cancer Research, United KingdomOTHER | 1 | Mar 19, 2020 | clinicaltrials |
| NCT00226954 | Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer | terminated | Phase 2 | 23 | Stanford UniversityOTHER | 1 | Mar 18, 2020 | clinicaltrials |
| NCT02028442 | Phase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer Patients(EVOLVE) | completed | Phase 1 / Phase 2 | 61 | Akamis BioINDUSTRY | 2 | Mar 12, 2020 | clinicaltrials |
| NCT02010203 | A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT | terminated | Phase 1 / Phase 2 | 104 | Heat BiologicsINDUSTRY | 1 | Feb 17, 2020 | clinicaltrials |
| NCT01094496 | A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study) | terminated | Phase 2 | 3 | Celldex TherapeuticsINDUSTRY | 1 | Feb 13, 2020 | clinicaltrials |
Data updated 24 days agoSource updated Sep 1, 2021source: clinicaltrials